Q2 2025 Amarin Corporation PLC Earnings Call Transcript
Key Points
- Amarin Corp PLC (AMRN) entered into a long-term licensing and supply agreement with Recordati to accelerate VASCEPA's commercialization in Europe.
- The company anticipates operating expense savings of approximately $70 million over the next 12 months due to global restructuring.
- VASCEPA has received regulatory approvals in 50 countries globally, enhancing its market potential.
- Amarin Corp PLC (AMRN) reported solid product sales growth in Europe and other key markets, with a 17% increase in market demand in Europe from Q1 2025.
- The company has a strong financial foundation with nearly $300 million in cash, zero debt, and sufficient inventory to meet global demand.
- Q2 2025 net product revenue in the US declined by 17% due to continued pricing pressure from generics.
- The company expects continued year-over-year revenue declines in the US market.
- Pricing pressure in the US market remains volatile, making future predictions challenging.
- The transition of commercialization efforts to Recordati in Europe is still in progress, with full control expected by the end of 2025.
- The timing of realizing value from strategic initiatives remains uncertain, with no defined timeline for potential strategic opportunities.
Good morning and welcome to Amarin Corporation's conference call to discuss its Second quarter 2025 financial results. I would now like to turn the conference over to Mr. Mark Marmur, Vice President, Corporate Communications and Investor Relations at Amarin. Sir, the floor is yours.
Good morning everyone and thank you for joining us. Please be aware that this conference call will contain forward-looking statements that are intended to be covered under the safe harbor provided under federal securities law. We may not achieve our goals, carry out our plans or intentions, or meet the expectations disclosed in our forward-looking statements.
Actual results or events could differ materially, so you should not place undue reliance on these statements. We assume no obligation to update these statements as circumstances change. Our forward-looking statements do not reflect the potential impact of significant transactions we may enter into, such as mergers, acquisitions, dispositions,
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
